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Abstract
Background: It is essential to investigate the serotype distribution of pneumococcal diseases in each region and its
associated clinical features. This study investigated the annual incidence of invasive pneumococcal disease (IPD)
and the distribution of serotypes of isolates causing IPD at a medical center in northern Taiwan during the period
2000 to 2012.
Methods: Serotypes of all available Streptococcus pneumoniae isolates causing IPD were determined using the latex
agglutination test.
Results: During the study period, the annual incidence (per 10,000 admissions) of IPD decreased significantly from
9.8 in 2000 to 2.1 in 2012 (P < 0.001). The annual incidence of all-cause bacteremia, primary pneumococcal
bacteremia, bacteremic pneumonia, peritonitis, and meningitis also decreased significantly during the study period
(P < 0.05). In contrast to the decrease in annual incidence of pneumococcal serotypes 14, 23F and 6B, the incidence
and the proportion of serotype 19A significantly increased with time (P < 0.001). The coverage rate of 7-valent
protein conjugated vaccine (PCV-7) and PCV-10 decreased significantly; however, the coverage rate of PCV-13 and
pneumococcal polysaccharide vaccine (PPV-23) remained stable over time. Serotype 14 and 19A isolates were
commonly isolated from blood and pleural effusion, respectively. Serotypes 14 and 23F were the two most
common serotypes found in adult patients, and serotypes 14 and 19A were the two most common serotypes
isolated from children.
Conclusions: Although the incidence of IPD has decreased, serotype 19A is an emerging problem in Taiwan.
The distribution of serotypes of pneumococci varied with clinical symptoms and age. As the changing distribution
of pneumococcal serotype with time, the coverage rate of pneumococcal vaccines would be different.
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Background
Streptococcus pneumoniae is a well known etiology of
acute otitis media, pneumonia, bloodstream infections,
peritonitis, and meningitis [1-5]. Although there are 92
different capsular serotypes, which have been catego-
rized into 46 serogroups based on immunological cha-
racteristics [6], less than 30 types account for more than
90% of invasive pneumococcal disease (IPD) [7]. Diffe-
rent serotypes have distinct features, which may be more
frequently associated with specific disease patterns. For
example, serotypes 3, 6B, 14, 23F can cause more severe
meningeal inflammation than serotypes 1, 5, 9, and 7F in
experimental meningitis [8,9]. In a murine model of
pneumococcal sepsis, certain serotypes were more fatal
than other serotypes [10]. Moreover, the distribution of
serotypes varies according to patient’s age, disease pat-
tern, and geographical region [1].
Although the mortality rate associated with IPD is as
high as 35% [11-14], pneumococcal vaccination was de-
veloped to prevent several serotypes. Furthermore, sero-
type distribution can be affected by the implementation
of vaccination [1]. Most important of all, novel vaccine
development should be based on knowledge of the inci-
dence rate of each pneumococcal serotype. When facing
this life-threatening disease, it is essential to investigate
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the serotype distribution in each region and its associated
clinical features. Therefore, we investigated the serotype
distribution of various types of IPD and the trend with
time from 2000 to 2012 at a medical center in Taiwan.
Methods
Hospital setting and patient selection
This study was conducted at the National Taiwan University
Hospital (NTUH). NTUH has a 2500-bed and around 8000
daily clinical visits, and is a both primary care and tertiary
care center in northern Taiwan. Patients whose blood,
cerebrospinal fluid (CSF), pleural effusion, ascites, or aspi-
rated ear and sinus fluid cultures yielded S. pneumoniae
during 2000–2012 were identified from the computerized
database of the bacteriology laboratory.
Bacterial isolates and serotype study
Pneumococcal isolates were identified by recognition of
typical colony morphology on trypticase soy agar supple-
mented with 5% sheep blood (BBL Microbiology Systems,
Cockeysville, MD), Gram staining characteristics, sus-
ceptibility to ethylhydrocupreine hydrochloride (optochin)
(Difco Laboratories, Detroit, MI) and bile solubility.
Serotypes were determined for available isolates by latex
agglutination (Pneumotest-Latex; Statens Serum Institut,
Copenhagen, Denmark) according to the manufacturer’s
instructions and were confirmed by the Quellung
reaction [15,16].
Definition
IPD was diagnosed in patients from whom S. pneumoniae
was isolated from a normally sterile site, such as blood,
cerebrospinal fluid, pleural fluid, or ascites. Pneumococcal
meningitis was diagnosed in patients from whom pneumo-
cocci were isolated from CSF. The diagnoses of pneumo-
coccal empyema, peritonitis, sinusitis, and otitis media
were established based on culture results positive for S.
pneumoniae obtained from pleural fluid, ascites, aspirated
sinus, and ear fluid, respectively. Primary pneumococcal
bacteremia was defined as isolation of pneumococcus from
blood without a focus. The annual incidence of each
type of IPD was defined as the number of patients with
pneumococcal infections per 10,000 admissions per year.
Statistical analysis
The chi-square test was used for dichotomous variables.
We used the chi-square test for trend to assess temporal
trends in incidence. A P value of < 0.05 was considered
to be statistically significant.
Results
Secular trend of incidence of IPD
During the study period, IPD was diagnosed in 458 pa-
tients and of those patients, 423 had bacteremia. Empyema
was found in 52 (11.4%) patients, peritonitis was found in
22 (4.8%) patients, and meningitis was found in 6 (1.3%)
patients. Additionally, 25 cases of culture-confirmed sinus-
itis and 25 cases of culture-confirmed otitis media were
identified during the study period. The yearly admission
number gradually increased with time (P < 0.05), ranging
from 55,920 in 2000 to 85,253 in 2012 (Table 1). The an-
nual incidence of each type of IPD per 10,000 admissions
is shown in Table 1 and Figure 1A and B. In children, the
annual incidence of IPD significantly decreased from 41.2
per 10,000 admissions in 2000 to 15.2 per 10,000 admis-
sions in 2012 (P < 0.001). In adult, the annual incidence of
IPD significantly decreased from 5.0 per 10,000 admissions
in 2000 to 1.5 per 10,000 admissions in 2012 (P < 0.001).
The overall annual incidence of IPD significantly decreased
from 9.8 per 10,000 admissions in 2000 to 2.1 per 10,000
admissions in 2012 (P < 0.001). Additionally, the annual
incidence of all-cause bacteremia, primary bacteremia,
bacteremic pneumonia, peritonitis, and meningitis due to
S. pneumoniae significantly decreased with time (P < 0.05).
The annual incidence of empyema, pneumonia without
bacteremia, sinusitis and otitis media remained stable be-
tween 2000 and 2012. Figure 1C shows the annual inci-
dence of major serotypes of S. pneumoniae causing IPD.
The annual incidence of serotypes 14, 23F and 6B signifi-
cantly decreased with time; however, the incidence of sero-
types 19A significantly increased (P <0.001). There was no
significant change in annual incidence of serotypes 3 and
19F (P = 0.172 and P = 0.08).
Serotype distribution in adults and children
During the study period, a total of 443 isolates from 443
patients with IPD were available for serotype studies.
The annual distribution of main capsular serotypes of
S. pneumoniae isolates causing IPD is shown in Figure 2.
For all patients, the proportion of serotype 19A increased
from <20% between 2000 and 2007 to 48.0%–50.0% be-
tween 2011 and 2012 (P < 0.001). Table 2 shows the
serotype distribution in adults, children, and all patients.
Among all patients, serotype 14 was the most common
serotype (n = 106, 23.9%), followed by serotype 23F (n = 57,
12.9%), and serotype 6B (n = 53, 12.0%). Serotype 14 was
also the most common serotype found in adult patients,
followed by serotype 23F, and 6B. In contrast, the second
most common serotype in children was serotype 19A,
followed by serotype 19F.
There was a significant increase in incidence of sero-
type 19A (P < 0.001), but a significant decline in inci-
dence of serotypes 14, 23F, and 6B over time. For adult
patients, the incidence of serotype 19A significantly in-
creased (P < 0.001). For children, the incidence of serotype
19A rose from <5% between 2000 and 2008 to 71.4%–
75.0% between 2011 and 2012 (P < 0.001). The incidence
of serotype 3 significantly increased (P < 0.001), but that of
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Table 1 Annual incidence of patients with each type of invasive pneumococcal disease (IPD), sinusitis, and otitis media at National Taiwan University Hospital
from 2000 to 2012



























IPD 9.8 7.6 8.0 5.9 8.4 4.6 4.0 3.0 4.6 3.6 3.8 3.1 2.1 <0.001
All bacteremia 9.3 7.3 7.1 5.1 7.9 4.1 3.8 2.9 4.2 3.4 3.4 2.7 1.9 <0.001
Primary
bacteremia
6.8 4.8 4.2 3.7 5.9 3.8 2.8 2.2 3.4 3.0 2.5 2.0 0.8 <0.001
Bacteremic
pneumonia
0.9 1.9 1.6 0.9 1.1 0.3 0.7 0.5 0.4 0.4 0.6 0.4 0.6 <0.001
Empyema 1.3 0.4 1.3 1.1 0.3 0.3 0.3 0.3 0.7 0.1 0.4 0.6 0.7 0.070
Peritonitis 0.4 0.1 0.2 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 < 0.009





16.8 18.4 24.1 19.1 23.2 23.4 27.1 23.0 25.6 22.1 23.5 15.0 12.7 <0.054
Sinusitis 0.2 0.3 0.3 0.2 0.6 0.3 0.3 0.4 0.4 0.0 0.3 0.1 0.2 0.439


















serotypes 23F and 19F significantly decreased (P = 0.027,
and P = 0.049).
Serotype distribution in different types of IPD
Blood was the most common source of isolates (n = 370,
83.5%), followed by pleural effusion (n = 46, 10.4%), CSF
(21, 4.7%), and ascites (n = 6, 1.4%). Serotype 14 (n = 88,
23.8%) was the most common serotype isolated from
blood specimens and serotype 19A (n = 14, 30.4%) was the
most common serotype isolated from pleural effusion. In
addition, serotype 6B was the most common serotype iso-
lated from CSF and serotype 19F was the most common
serotype isolated from ascites specimens.
Vaccine coverage
The coverage rates of conjugated vaccines including PCV-7
(PrevnarR; Pfizer), PCV-10 (Synflorix; GSK), PCV-13
(Prevnar 13; Pfizer) and PPV-23 (Pneumovax 23; Merck
Figure 1 Annual incidence (number of patients per 10,000 admissions) of invasive pneumococcal disease (IPD). (A) Annual incidence of
IPD among adults and children, major type of IPD (B), and major pneumococcal serotype (C).
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Sharp & Dohme Corp.) are shown in Figure 3. The overall
coverage rates during the period 2000–2012 were 65.2%
for PCV-7, 65.9% for PCV-10, 85.8% for PCV-13, and
91.2% for PPV-23. The coverage rates of PCV-7 and PCV-
10 significantly decreased with time, but the PCV-13 and
PPV-23 coverage rates remained stable. Moreover, PCV-7
and PCV-10 had only a 25% coverage rate in 2012. In con-
trast, the coverage rates of PCV-13 and PCV-23 were each
80.0% in 2012. The reason coverage of PCV-13 was better
than that of PPV-23 in 2010 and 2011 is that there were
four serotype 6A isolates found in 2010 and two serotype
6A isolates found in 2011 that were covered by PCV-13
but not by PPV-23.
Discussion
This study investigated the epidemiology of IPD and the
trends and changes in distribution of pneumococcal sero-
types in a large Taiwanese hospital over a 13 year period.
We found that the incidence of most pneumococcal dis-
eases, including all-cause bacteremia, primary bacteremia,
bacteremic pneumonia, peritonitis, and meningitis, sig-
nificantly decreased with time during study period. In
addition, the annual incidence of several pneumococcal
serotypes, including serotypes 14, 23F, and 6B significantly
decreased with time. In Taiwan, PPV-23 was introduced
in 2001 and the cumulative vaccination rate among people
aged ≥75 years reached 12% in 2007 and 41% in 2008.
Figure 2 Distribution of serotypes among S. pneumoniae isolates. (A), children (B) and all patients with invasive pneumococcal diseases (C).
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PCV-7 was introduced in October 2005 and the cumula-
tive vaccination rate among children aged <5 years was
0.7% in 2005, 8.6% in 2006, 15.9% in 2007, and 25.2% in
2008 [16]. In contrast, PCV-10 and PCV-13 were intro-
duced in Taiwan in 2010, and 2011, respectively. There-
fore, our encouraging finding can be attributed to the
introduction of PPV-23 and PCV-7. However, we found
an increase in the incidence and proportion of serotype
19A among all serotypes causing IPD, especially in chil-
dren. Although PPV-23 can cover serotype 19A, the use
of this vaccine is limited in elderly patients with age above
65 years. Therefore, the emergence of serotype 19A, espe-
cially in children in Taiwan may be due to inadequate
coverage of vaccination. Moreover, our findings suggest
that the secular trend in pneumococcal serotype distribu-
tion needs to be closely monitored and that the use
of vaccination needs to be adjusted according to the
change in serotype distribution.
We found that the coverage rate of PCV-7 and PCV-
10 declined from more than 80% in 2000 to 20% in
2012. In contrast, that of PPV-23 and PCV-13 remained
stable, ranging from 75% to 97% during the study period.
The difference can be attributed to the fact that PPV-23
and PCV-13 cover serotypes 19A and 3. Moreover, PCV-13
Table 2 Distribution of major serotypes of 443 isolates of
S. pneumoniae causing invasive pneumococcal disease in
adults and children treated National Taiwan University
Hospital from 2000 to 2012
Serotype Adults (n = 275) Children (n = 168) Total (n = 443)
No. % No. % No. %
14 60 21.9 46 27.4 106 23.9
23F 42 15.3 15 8.9 57 12.9
6B 33 12.0 20 11.9 53 12.0
3 31 11.3 7 4.2 38 8.6
19F 30 10.9 17 10.1 47 10.6
4 9 3.3 0 0.0 9 2.0
19A 9 3.3 33 19.6 42 9.5
9V 7 2.5 5 3.0 12 2.7
23A 7 2.5 1 0.6 8 1.8
15B 5 1.8 9 5.4 14 3.2
20 5 1.8 2 1.2 7 1.6
Others 37 13.5 13 7.7 50 11.3
Total 275 100 168 100 443 100
Figure 3 Coverage rates of different pneumococcal vaccines among S. pneumoniae isolates recovered from patients with invasive
pneumococcal diseases at National Taiwan University Hospital from 2000 to 2012.
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can cover serotype 6A but PPV-23 cannot. All of the 8
cases of serotype 6A isolates were found within the last
four years (2009 to 2012). Therefore, the clinical impact of
PCV-13 for serotype 6A deserves further attention. Based
on our findings, PPV-23 and PCV-13 may be a better choice
of vaccine to prevent IPD in Taiwan. However, PCV-13 is
a newly introduced vaccine in Taiwan; therefore, further
surveillance studies are warranted.
We also found that the serotype distribution differed
among different diseases. For example, serotype 14 was the
most common serotype causing pneumococcal bacteremia
in both adults and children [17] and was also the predom-
inant serotype causing empyema in children. In addition to
serotype 14, serotypes 3, 6B, 19F, and 23F were the most
common serotypes causing bacteremia in adults. In chil-
dren, serotypes 6B, 19A, 19F, and 23F were common
serotypes causing bacteremia. In addition, most cases
of meningitis in children and adults were caused by ser-
ogroups 6 (n = 7), and 23 (n =5). In contrast, only one pa-
tient had serotype 14 meningitis. This finding is consistent
with a previously reported finding that serogroups 6, 10,
and 23 are more frequently isolated from CSF than sero-
types 1, 4, and 14 [17]. Serotype 19F was isolated from 4
of the 6 patients with pneumococcal peritonitis. We also
found that some uncommon serotypes were associated
with their own distinct syndromes. For example, all pa-
tients (n = 9) with serotype 4 and all patients (n = 3) with
serotype 22F were adults with bacteremia. In summary,
our findings as well as those reported previously [17-20]
suggest that some serotypes have a propensity to invade
one clinical site rather than another and may therefore be
disproportionately responsible for certain disease manifes-
tations. In the present study, serotypes 19A, 14, and 23F
were the most common strains causing empyema. This
finding differs from that reported in a recent UK study
[21], which showed that serotypes 1, 3, 7F, and 19A were
most frequently implicated in pneumococcal parapneu-
monic effusion. This difference may be due to geograph-
ical differences.
We also found that the distribution of serotypes dif-
fered among different age groups. Although serotype 14
was the predominant serotype in adults and children,
the second most common serotype differed between the
two age groups. In addition, although serotype 19A was
the second most common serotype in children (14.9%),
only 2.7% of cases of IPD in adult patients were caused
by serotype 19A pneumonococcus. This finding is simi-
lar to that recently reported in a study from China,
which demonstrated that serotype 19A strains were
more frequently isolated from children with IPD [22].
However, our findings differed from those recently re-
ported in a study from Argentina, which showed that se-
rotypes 14, 1, 19A, 5, 12F, 6B, and 18C were the most
prevalent serotypes in patients with IPD [23]. In our
study, serotype 23A was the second most common sero-
type in adult patients (15.9%), but only accounted for
9.7% of cases of IPD in children. In addition, serotype 4
only caused pneumococcal infection in nine adult pa-
tients. The above-mentioned findings suggest that the
distribution of pneumococcal serotypes varies according
to different age groups.
This study had one major limitation. We might not
have captured all cases of IPD because changes might
occur in practices that could have affected rates of culture
collection or culture positivity. However, this 13-year lon-
gitudinal investigation in a medical center in Taiwan still
provided the useful information concerning epidemiology
of IPD, and possible impact of pneumococcal vaccination.
Most important of all, it might help to guide our govern-
ment in the implementation of an effective pneumococcal
vaccination program.
Conclusions
Despite we might have missed some cases of IPD in
this study, we found that IPD caused by serotype 19A
S. pneumoniae is an emerging problem in Taiwan, al-
though the incidence of IPD has decreased. The distribu-
tion of serotypes of pneumococcal isolates causing IPD
varies according to clinical syndromes, and age. As the
changing distribution of pneumococcal serotype with time,
the coverage rate of each pneumococcal vaccine would be
different.
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